Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer

Curasight to develop its proprietary uTRACE® PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization The agreement supports Curasight’s strategy to leverage...

Taggar: curasight, curium, announce